Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 14/20 | 0.53 |
| ▸ | CNR1 | P21554 | 4/20 | 0.53 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4733693 | 0.90 | CNR2 (0.53) | CNR2CNR1PDCD1CD274ABL1 | |
| SCHEMBL14206962 | 0.88 | CNR2 (0.45) | CNR2CNR1PDCD1CD274F10 | |
| SCHEMBL4783553 | 0.81 | CNR2 (0.53) | CNR2CNR1 | |
| SCHEMBL4732697 | 0.80 | CNR2 (0.53) | CNR2CNR1ABL1 | |
| SCHEMBL14207105 | 0.78 | CNR2 (0.64) | CNR2CNR1BRD4 | |
| SCHEMBL14314466 | 0.75 | CNR2 (0.59) | CNR2CNR1BRD4ABL1 | |
| SCHEMBL4781327 | 0.75 | CNR2 (0.60) | CNR2CNR1BRD4 | |
| SCHEMBL4731505 | 0.74 | CNR2 (0.59) | CNR2CNR1BRD4MAP4K1 | |
| SCHEMBL4733593 | 0.74 | CNR2 (0.52) | CNR2CNR1 | |
| SCHEMBL4730502 | 0.73 | CNR2 (0.53) | CNR2CNR1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008063625-A2 | PYRIDINE COMPOUNDS AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2008-05-29 | — | — | WO | claimed |
| WO-2008063625-A2 | PYRIDINE COMPOUNDS AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2008-05-29 | — | — | WO | disclosed |